The first Chaperone Therapy for Fabry patients.

Shares

Excited to share Health Canada’s approval of the oral- precision medicine Galafold! We look forward to this differentiated treatment option for Canadian patients with amenable mutations. Please see the press release for further information.

Close

Contact Us

If have any questions or would like to get involved, please fill in the form below.

Subscribe error, please review your email address.

Close

You're now subscribed, thank you!

Close

There was a problem with your submission. Please check the field(s) with red label below.

Close

Your message has been sent. We'll get back to you soon!

Close